Volume 55, Issue 3, Pages 1063-1071 (March 1999) Circulating vascular endothelial growth factor is not increased during relapses of steroid- sensitive nephrotic syndrome  Nicholas J.A. Webb, Carolyn J. Watson, I.A.N.S.D. Roberts, Martyn J. Bottomley, Caroline A. Jones, Malcolm A. Lewis, Robert J. Postlethwaite, Paul E.C. Brenchley  Kidney International  Volume 55, Issue 3, Pages 1063-1071 (March 1999) DOI: 10.1046/j.1523-1755.1999.0550031063.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 (A) Plasma vascular endothelial growth factor (VEGF) levels in children with steroid-sensitive nephrotic syndrome (in relapse and remission) and age- and sex-matched normal controls. P = 0.295, Kruskal–Wallis test. (B) Urinary VEGF/Cr ratios in children with steroid-sensitive nephrotic syndrome (in relapse and remission) and age- and sex-matched normal controls. P = 0.632, Kruskal–Wallis test. Horizontal bars denote median values. Kidney International 1999 55, 1063-1071DOI: (10.1046/j.1523-1755.1999.0550031063.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 (A) Blood pressure (mean ± SEM) in Sprague-Dawley rats prior to, during, and for 60 minutes after the administration of rVEGF165 (50 μg; N = 5) or 0.9% saline (N = 5). Symbols are: (▪) VEGF-administered animals; (▴) saline-administered animals. (B) Urine output (mean ± SEM) in Sprague-Dawley rats prior to and following administration of rVEGF165 (50 μg; N = 5) or 0.9% saline (N = 5). (C) Urinary protein excretion (mean ± SEM) by Sprague-Dawley rats following administration of rVEGF165 (50 μg; N = 5) or 0.9% saline (N = 5). Kidney International 1999 55, 1063-1071DOI: (10.1046/j.1523-1755.1999.0550031063.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 (A) Urine output (mean ± SEM) in Sprague-Dawley rats prior to and following the administration of rVEGF165 (50 μg; N = 4) or 0.9% saline (N = 4). Symbols are: (▪) VEGF-administered animals; (▴) saline-administered animals. (B) Urinary protein excretion (mean ± SEM) in Sprague-Dawley rats prior to and following administration of rVEGF165 (50 μg; N = 4) or 0.9% saline (N = 4). Kidney International 1999 55, 1063-1071DOI: (10.1046/j.1523-1755.1999.0550031063.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Kidney International 1999 55, 1063-1071DOI: (10. 1046/j. 1523-1755 Kidney International 1999 55, 1063-1071DOI: (10.1046/j.1523-1755.1999.0550031063.x) Copyright © 1999 International Society of Nephrology Terms and Conditions